Diseño y evaluación de un programa de rehabilitación cardíaca (CARE) exclusivo para mujeres (CARE)
Diseño y evaluación de un programa de rehabilitación cardíaca exclusivo para mujeres
The purpose of this randomized controlled study is to investigate the effect(s) of a pilot women-only cardiac rehabilitation (CR) program. The study team will be testing the effectiveness, compliance and enjoyment of this women's only cardiac rehabilitation (CR) program by comparing outcomes to those randomized to receive Michigan Medicine's current CR program (standard care), which includes people of all genders.
Study hypotheses:
- Women randomized to women-specific CR programming will have superior attendance and completion rates compared to women attending mixed-sex CR programming.
- Women randomized to women-specific CR programming will experience greater improvement in clinical outcomes in comparison to those in mixed-sex CR programming.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This registration was updated on 11/24/2025 due to amendments that were approved at the IRBMED.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Beth Perrotta
- Número de teléfono: 734-232-6865
- Correo electrónico: eperrott@umich.edu
Ubicaciones de estudio
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Reclutamiento
- University of Michigan
-
Contacto:
- Beth Perotta
- Número de teléfono: 734-232-6865
- Correo electrónico: eperrott@umich.edu
-
Investigador principal:
- Melvyn Rubenfire, MD
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability to participate in study procedures for the duration of the study
- Identify as a female
- Be between the ages of 40-80 years, inclusive
- Documented diagnosis of CR indications of stable and/or refractory angina pectoris (with or without coronary obstructive disease), acute myocardial infarction (MI) within the preceding 12 months (including MINOCA), percutaneous coronary interventions (PCI), surgical and transvalvular aortic valve replacement, spontaneous coronary artery dissection (SCAD), post-aortic surgery with or without aortic valve, coronary artery bypass grafting (CABG) and mitral valve replacement or repair with or without CABG
- Referred to outpatient CR at the University of Michigan, Domino's Farms or Brighton Center for Specialty Care Cardiac Rehabilitation site based on Michigan Medicine's Division of Cardiovascular Medicine Policy and Procedure.
Exclusion Criteria:
- Not being "cleared" for CR based on Michigan Medicine's Division of Cardiovascular Medicine Policy and Procedures
- Prior participation in CR
- Inability to understand spoken and written English, either due to language barrier or cognitive limitation for any reason, including deaf or blind
- Frailty, fall risk, or muscle, joint or back pain as defined as the inability to perform activities of daily living without limitations and engage in mild physical activity (i.e. unable to walk up 1 flight of stairs unaided)
- Any of the following as the indication for CR: aortic repair or replacement for aortic dissection, untreated or greater than New York Heart Association (NYHA) class II congestive heart failure, cardiac transplant candidate or recipient, tricuspid or pulmonic valve repair or replacement
- Life threatening ventricular arrythmias without an implanted defibrillator; very frequent premature ventricular contraction or premature atrial contractions symptomatic or not; poorly controlled atrial fibrillation
- Associated more than mild valvular heart disease, untreated congestive heart failure; unstable angina or heart pain with minimal activity; angina or congestive heart failure limiting ability to climb one flight of stairs without help (NHYA Functional Classification >2)
- Severe pulmonary hypertension (right heart systolic pressure greater than 60 millimeters of mercury); clot in the heart; treated venous thrombosis with or without pulmonary embolism in past 6 months; more than mild dyspnea related to chronic lung disease or asthma
- Chronic kidney disease (creatinine >2 milligrams per deciliter (mg/dl)); symptomatic active liver disease (infectious or inflammatory), symptomatic chronic liver disease (except for nonalcoholic fatty liver disease), kidney dialysis or kidney transplant recipient, active or chronic renal disease (rise by 0.5mg/dL in past 3 months or chronic elevated serum creatinine 2.0 milligrams per milliliter (mg/mL) or greater.
- Poorly controlled diabetes defined as uninterrupted HbA1c >8.0% for ≥1 year despite standard care, baseline HbA1c prior to CR > 8.5%.
- Immunosuppressive drug requirement, acute anemia, chronic anemia with Hemoglobin < 10mg/mL
- Limiting chronic muscle, joint, or back pain; identified as fall risk from poor balance or neurologic syndromes; frailty defined as the inability to perform activities of daily living in older adults that carries an increased risk for poor health outcomes including falls, incident disability, hospitalization, and mortality
- Untreated or active substance abuse/addiction including alcohol and drugs; depression (defined as a score ≥ 15 or depression positive answer to #8 or #9 on Patient Health Questionnaire-9) unless deemed acceptable by mental health care provider; severe anxiety
- Severe obesity (Body mass index ≥ 40 kilograms/meters squared), history of bariatric surgery within previous 3 years and >5% body weight loss over preceding 12 months; chronic venous insufficiency with cellulitis or > 1+ edema unless controlled with support hose.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Programa de rehabilitación cardíaca solo para mujeres
|
This is a 12-week program and will include 36 sessions 3 times a week. This group will also have Women-Only Education sessions. Participants will also have a 24-week follow-up visit from the time of entry. Women-specific education content will be provided monthly in addition to the standard weekly "mini-teaches." This education content will be developed and delivered by experience health care professionals that are experts in women's health. |
|
Comparador activo: Programa de rehabilitación estándar de atención (mixto)
|
This is a 12-week program and will include up to 36 sessions 3 times a week. Participants will also have a 24-week follow-up visit from the time of entry. Exercise classes are medically supervised, and each program is individualized based upon medical history, cardiac risk factors, goals, and initial fitness level. Educational programs are arranged in a continuing series, with sessions taught by experts in nutrition therapy, stress reduction therapy, and exercise. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cardiac Rehabilitation (CR) attendance rate
Periodo de tiempo: 12 weeks (post CR)
|
CR completion rate defined as number of patients that "graduated" or completed CR programming versus the number of patients that started CR programming [i.e. attended 75% or more of the prescribed sessions (≥27 out of 36)], expressed as a percentage of participants per arm. |
12 weeks (post CR)
|
|
Cardiac Rehabilitation (CR) attendance rate - percentage
Periodo de tiempo: 12 weeks (post CR)
|
Number of CR sessions attended out of number of CR sessions prescribed, expressed as a percentage |
12 weeks (post CR)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Optimal blood pressure (BP) control
Periodo de tiempo: 12 weeks (post CR)
|
Percentage of patients that have optimal BP control at program discharge, defined as systolic blood pressure (SBP) less than 130 mmHg and diastolic blood pressure (DBP) less than 80 Millimeters of mercury (mmHg). |
12 weeks (post CR)
|
|
Change in resting systolic blood pressure (SBP)
Periodo de tiempo: Baseline, 12 weeks (post CR)
|
Change in resting SBP from baseline to CR completion, measured using an automated blood pressure monitor and expressed in mmHg. |
Baseline, 12 weeks (post CR)
|
|
Change in resting diastolic blood pressure (DBP)
Periodo de tiempo: Baseline, 12 weeks (post CR)
|
Change in resting DBP from baseline to CR completion, measured using an automated blood pressure monitor and expressed in mmHg. |
Baseline, 12 weeks (post CR)
|
|
Improvement in depression based on the Patient Health Questionnaire (PHQ)-9
Periodo de tiempo: Baseline to 12 weeks (post CR)
|
Percentage (%) of patients with a positive depressive screen at CR entrance that experience a decrease in depressive symptoms (reduction in one or more levels of severity) as measured by changes in the Patient Health Questionnaire (PHQ)-9 score from baseline to completion of CR. The PHQ-9 questionnaire is a self-assessed questionnaire that asks participants to respond to 9 questions with response options of 0, 1, 2 or 3. The total score scale ranges from 0 to 27. Higher scores indicate more symptoms of depression. |
Baseline to 12 weeks (post CR)
|
|
Change in Patient Health Questionnaire (PHQ)-9 score
Periodo de tiempo: Baseline to 12 weeks (post CR)
|
A change in PHQ-9 scores will be measured during the first 12 weeks of the study. The PHQ-9 questionnaire is a self-assessed questionnaire that asks participants to respond to 9 questions with response options of 0, 1, 2 or 3. The total score scale ranges from 0 to 27. Higher scores indicate more symptoms of depression. |
Baseline to 12 weeks (post CR)
|
|
Change in Patient Health Questionnaire (PHQ)-9 score
Periodo de tiempo: 12 weeks (post CR), 24 weeks
|
The PHQ-9 questionnaire is a self-assessed questionnaire that asks participants to respond to 9 questions with response options of 0, 1, 2 or 3. The total score scale ranges from 0 to 27. Higher scores indicate more symptoms of depression. A change in PHQ-9 scores will be measured during the first 12 weeks of the study and will be repeated 12 weeks following program completion. |
12 weeks (post CR), 24 weeks
|
|
Improvement in functional capacity measured by the six-minute walk test
Periodo de tiempo: Baseline, up to 12 weeks (post CR)
|
Percentage of patients that achieve an increase in distance walked, in meters, by at least 10%, after participation in CR as measured by the 6-minute walk test (6MWT). |
Baseline, up to 12 weeks (post CR)
|
|
Change in 6-minute walk test distance
Periodo de tiempo: Baseline, 12 weeks (post CR)
|
The distance walked in six minutes on a standard course will be measured in meters at baseline and CR Exit |
Baseline, 12 weeks (post CR)
|
|
Improvement in functional capacity Metabolic Equivalents (METs)
Periodo de tiempo: Baseline, 12 weeks (post CR)
|
Percentage of patients that display an overall mean increase in estimated METs (0.93 METs, 12.4%): with greatest increase occurring in "low" fitness patients < 5 METs (1.3 METs, 35% increase), followed by "moderate" fitness 5-8 METs (1.03 METs, 16% increase), and "high" fitness > 8 METs (0.77 METs, 8% increase)2,3 after participation in CR as measured by estimated exercise session peak METs. |
Baseline, 12 weeks (post CR)
|
|
Change in estimated exercise session peak METs
Periodo de tiempo: Baseline, up to 12 weeks (post CR)
|
The difference in estimated peak METs between baseline (defined as the third session to account for learning effect) and program completion. |
Baseline, up to 12 weeks (post CR)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Melvyn Rubenfire, MD, University of Michigan
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- HUM00252649
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .